Virpax Pharmaceuticals, Inc. (Virpax), a preclinical-stage pharmaceutical company, has filed a registration statement with the Securities and Exchange Commission (SEC) on July 29, 2024, for a proposed public offering of its common stock and pre-funded warrants. The offering includes an undisclosed number of shares and pre-funded warrants, with each warrant exercisable for one share of common stock at an exercise price of $0.00001 per share. The warrants are immediately exercisable and may be exercised at any time until fully exercised. RBW Capital Partners LLC, acting through Dominari Securities LLC, has been engaged as the exclusive placement agent for the offering on a reasonable best-efforts basis. The offering is expected to close one business day following its commencement. Virpax intends to use the net proceeds from the offering to fund ongoing activities related to their planned Investigational New Drug (IND) filing for Probudur, as well as for working capital and other general corporate purposes. The company's common stock is listed on the Nasdaq Capital Market under the symbol 'VRPX'.

Virpax Pharmaceuticals, Inc. (Virpax), a preclinical-stage pharmaceutical company, has filed a registration statement with the Securities and Exchange Commission (SEC) on July 29, 2024, for a proposed public offering of its common stock and pre-funded warrants. The offering includes an undisclosed number of shares and pre-funded warrants, with each warrant exercisable for one share of common stock at an exercise price of $0.00001 per share. The warrants are immediately exercisable and may be exercised at any time until fully exercised. RBW Capital Partners LLC, acting through Dominari Securities LLC, has been engaged as the exclusive placement agent for the offering on a reasonable best-efforts basis. The offering is expected to close one business day following its commencement. Virpax intends to use the net proceeds from the offering to fund ongoing activities related to their planned Investigational New Drug (IND) filing for Probudur, as well as for working capital and other general corporate purposes. The company's common stock is listed on the Nasdaq Capital Market under the symbol 'VRPX'.